|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 7 |
| 2 | Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients显示文摘Objective: Germline alterations in the breast cancer susceptibility genes type 1 and 2, BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers.Accumulating evidence suggests inherited genetic susceptibility to lung cancer.The present study aimed to survey the prevalence of pathogenic germline BRCA mutations(gBRCAm) and explore the potential association between gBRCAm and disease onset in Chinese advanced non-small cell lung cancer(NSCLC) patients.Methods: A total of 6,220 NSCLC patients were screened using capture-based ultra-deep targeted sequencing to identify patients harboring germline BRCA1/2 mutations.Results: Out of the 6,220 patients screened, 1.03%(64/6,220) of the patients harbored the pathogenic gB RCAm, with BRCA2 mutations being the most predominant mutations(49/64, 76.5%).Patients who developed NSCLC before 50 years of age were more likely to carry gBRCAm(P = 0.036).Among the patients harboring classic lung cancer driver mutations, those with concurrent gBRCAm were significantly younger than those harboring the wild-type gBRCA(P = 0.029).By contrast, the age of patients with or without concurrent gBRCAm was comparable to those of patients without the driver mutations(P = 0.972).In addition, we identified EGFR-mutant patients with concurrent gBRCAm who showed comparable progression-free survival but significantly longer overall survival(P = 0.002) compared to EGFR-mutant patients with wild-type germline BRCA.Conclusions: Overall, our study is the largest survey of the prevalence of pathogenic gBRCAm in advanced Chinese NSCLC patients.Results suggested a lack of association between germline BRCA status and treatment outcome of EGFR-TKI.In addition,results showed a positive correlation between pathogenic gB RCAm and an early onset of NSCLC. | Xingsheng Hu Dongyong Yang Yalun Li Li Li Yan Wang Peng Chen Song Xu Xingxiang Pu Wei Zhu Pengbo Deng Junyi Ye Hanhan Zhang Analyn Lizaso Hao Liu Xinru Mao Hai Huang Qian Chu Chengping Hu | 2019 | Cancer Biology & Medicine2019，16，3： | 4 |
| 3 | Effect of molybdenum on diamond deposition and adhesion显示文摘 | Huang Yuansheng Qiu Wanqi Luo Chengping | 2005 | Thin Solid Films2005，472，： | 1 |
| 4 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 5 | Clinical characteristics and prognostic significance of 92 cases ofpatients with primary mixed?histology lung cancer显示文摘 | Pengbo Deng Chengping Hu Lihua Zhou Yuanyuan Li Li Huang | 2013 | Molecular and Clinical Oncology2013，，5： | 1 |
| 6 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 7 | Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients显示文摘In the published article1,the affiliation for the first author,Xingshcng Hu,is'Department of Medical Oncology,Cancer Hospital,Chinese Academy of Medical Sciences',we would like to update it to'Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China'.We apologize for the errors and for any confusion it may have caused. | Xingsheng Hu Dongyong Yang Yalun Li Li Li Yan Wang Peng Chen Song Xu Xingxiang Pu Wei Zhu Pengbo Deng Junyi Ye Hanhan Zhang Analyn Lizaso Hao Liu Xinru Mao Hai Huang Qian Chu Chengping Hu | 2020 | Cancer Biology & Medicine2020，17，2： | 1 |
| 8 | Effect of molybdenum on diamond deposition and adhesion 显示文摘 | Huang Yuansheng Qiu Wanqi Luo Chengping | 2005 | Thin Solid Films2005，472，12： | 1 |
| 9 | High-speed 3-D shape measurement based on digital ~ringe projection 显示文摘 | Huang Peisen Zhang Chengping Chiang Fupen | 2003 | Optical Engineering2003，42，1： | 1 |
| 10 | Split- ting of transmission peak due to the hole symmetry breaking显示文摘 | Yin Xiaogang Huang Chengping Shen Zhiqiang | 2009 | Appl Phys Lett2009，94，16： | 1 |
| 11 | Dual effect of surface plasmons in light transmission through per- forated metal films显示文摘 | Huang Chengping Wang Qianjin Zhu Yongyuan | 2007 | Phys Rev B2007，75，24： | 1 |
| 12 | High-speed 3-D shape measurement based on digital fringe projection显示文摘 | Huang Peisen S Zhang Chengping Chiang Fu-Pen | 2003 | Optical Engineering2003，42，1： | 1 |
| 13 | High-speed 3-D shape measurement based on digital fringe projection显示文摘 | Peisen S Huang Chengping Zhang Fu-Pen Chiang | 2003 | Opt Eng2003，42，1： | 1 |
| 14 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 15 | Effect of molybdenum on diamond deposition and adhesion显示文摘 | Huang Yuansheng Qiu Wanqi Luo Chengping | 2005 | Thin Solid Films2005，472，12： | 1 |
| 16 | Highspeed phase shifting profilometry 显示文摘 | Huang Peisen S Chiang Fu Pen | 2001 | Proc SPIE2001，4189，： | 1 |
| 17 | Treatment Effects of Integrated TCM and Western Medicine Treatment Scheme on COVID-19: A Single-armed Clinical Trial显示文摘Backgroud:The outbreak of COVID-19 has brought unprecedented perils to human health and raised public health concerns in more than two hundred countries.Safe and effective treatment scheme is needed urgently.Objective:To evaluate the effects of integratedTCM and western medicine treatment scheme on COVID-19.Methods:A single-armed clinical trial was carried out in Hangzhou Xixi Hospital,an affiliated hospital with Zhejiang Chinese Medical University.102 confirmed cases were screened out from 725 suspected cases and 93 of them were treated with integrated TCM and western medicine treatment scheme.Results:83 cases were cured,5 cases deteriorated,and 5 cases withdrew from the study.No deaths were reported.The mean relief time of fever,cough,diarrhea,and fatigue were(4.78±4.61)days,(7.22±4.99)days,(5.28±3.39)days,and(5.28±3.39)days,respectively.It took(14.84±5.50)days for SARS-CoV-2 by nucleic acid amplification-based testing to turn negative.Multivariable cox regression analysis revealed that age,BMI,PISCT,BPC,AST,CK,BS,and UPRO were independent risk factors for COVID-19 treatment.Conclusion:Our study suggested that integrated TCM and western medicine treatment scheme was effective for COVID-19. | Jianfeng Bao Zhijun Xie Shourong Liu Lin Huang Jing Sun Yujun Tang Haiping Chen Jianjiang Qi Jianchun Guo Liangbin Miao Zhaoyi Li Hui Yang Yi Zhang Zhiyu Li Yuan Xu Shengyou Lin Yunhao Xun Li Zhang Jie Bao Zhaobin Cai Jinsong Huang Chengping Wen | 2021 | Clinical Complementary Medicine and Pharmacology2021，1，1： | 0 |
| 18 | Neddylation is a novel therapeutic target for lupus by regulating double negative T cell homeostasis显示文摘Systemic lupus erythematosus(SLE),a severe autoimmune disorder,is characterized by systemic inflammatory response,autoantibody accumulation and damage to organs.The dysregulation of double-negative(DN)T cells is considered as a crucial commander during SLE.Neddylation,a significant type of protein post-translational modification(PTM),has been well-proved to regulate T cell-mediated immune response.However,the function of neddylation in SLE is still unknown.Here,we reported that neddylation inactivation with MLN4924,a specific inhibitor of NEDD8-activating enzyme E1(NAE1),or genetic abrogation of Ube2m in T cells decreased DN T cell accumulation and attenuated murine lupus development.Further investigations revealed that inactivation of neddylation blocked Bim ubiquitination degradation and maintained Bim level in DN T cells,contributing to the apoptosis of the accumulated DN T cells in lupus mice.Then double knockout(KO)lupus-prone mice(Ube2m-/-Bim-/-lpr)were generated and results showed that loss of Bim reduced Ube2m deficiency-induced apoptosis in DN T cells and reversed the alleviated lupus progression.Our findings identified that neddylation inactivation promoted Bim-mediated DN T cell apoptosis and attenuated lupus progression.Clinically,we also found that in SLE patients,the proportion of DN T cells was raised and their apoptosis was reduced.Moreover,compared to healthy groups,SLE patients exhibited decreased Bim levels and elevated Cullin1 neddylation levels.Meantime,the inhibition of neddylation induced Bim-dependent apoptosis of DN T cells isolated from SLE patients.Altogether,our findings provide the direct evidence about the function of neddylation during lupus,suggesting a promising therapeutic approach for this disease. | Yun Zhang Lijun Du Chenxi Wang Zhangsheng Jiang Qingchi Duan Yiping Li Zhijun Xie Zhixing He Yi Sun Lin Huang Liwei Lu Chengping Wen | 2024 | Signal Transduction and Targeted Therapy2024，9，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员